Dilpacimab is under clinical development by AbbVie and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dilpacimab’s likelihood of approval (LoA) and phase transition for Ovarian Cancer took place on 17 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 17 Oct 2022 increased Dilpacimab’s Phase Transition Success Rate (PTSR) for Solid Tumor.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dilpacimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dilpacimab overview

Dilpacimab (ABT-165) is under development for the treatment of advanced solid tumors like ovarian cancer. The drug candidate is administered as intravenous infusion. The drug candidate is a dual variable domain immunoglobulin. The target-binding variable domains of antibody can be combined via naturally occurring linkers to create a tetravalent, a dual-targeting single agent. It was under development for breast cancer, glioblastoma multiforme, pancreatic cancer and metastatic colorectal cancer.

AbbVie overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

Quick View Dilpacimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Dilpacimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.